col blocks we are bridge builder col blocks
COVID Antworten in den wissenschaftlichen Zeitschriften der Welt


35 Ergebisse       Seite 1

 [1] 
Elsevier: Immunology Letters
  Original Artikel Datum Titel Autoren   Alle Autoren
1 [GO] 2023―Nov―24 Platelet dropping, bleeding and new treatment requirements in ITP patients after inactivated COVID-19 vaccination Xiao-Yong Zhan, Hui Chen, Huimin Kong, Tongfei Meng, Jieyu Ye, Yong Liu, et al. (+8)
2 [GO] 2023―Sep―06 USE OF RECOMBINANT S1 PROTEIN WITH hFc FOR ANALYSIS OF SARS-COV-2 ADSORPTION AND EVALUATION OF DRUGS THAT INHIBIT ENTRY INTO VERO E6 CELLS Jéssica Carla Martins Couto, Taís Vidal, Eduardo Reichert Decker, Janio M Santurio, Carlos Fernando de Mello, Micheli Mainardi Pillat
3 [GO] 2023―Aug―18 Pre-infection antibody levels of vaccinated healthcare workers with SARS-CoV-2 breakthrough infection: A nested case-control study Sema Alp Çavuş, Muammer Çelik, Ahmet Furkan Süner, Irmak Güzel, Çağlar Irmak, Derya Çağlayan, et al. (+9)
4 [GO] 2023―Jun―18 Serum profiles of pro-inflammatory and anti-inflammatory cytokines in non-hospitalized patients with mild/moderate COVID-19 infection. Abdulraheem Y. Majeed, Nor Effa S. Zulkafli, Ali H. Ad'hiah
5 [GO] 2023―Jun―03 Myocarditis Development After COVID-19 Vaccination in an Immunodeficient Case Öner Özdemir, Elif Şeker, Ümmügülsüm Dikici, Muhammed Güneş
6 [GO] 2023―Mai―24 Inactivated COVID-19 vaccines: potential concerns of antibody-dependent enhancement and original antigenic sin Andy Ka Chun Kan, Philip Hei Li
7 [GO] 2023―Jan―23 Immunothrombosis biomarkers as potential predictive factors of acute respiratory distress syndrome in moderate-to-critical COVID-19: a single-center, retrospective cohort study Giou-Teng Yiang, Yao-Kuang Wu, Kuo-Wang Tsai, I-Shiang Tzeng, Wan-Chung Hu, Min-Tser Liao, et al. (+4)
8 [GO] 2023―Jan―02 Does infection with Leishmania protect against Covid-19? Nasreddine Saidi, Refka Jelassi
9 [GO] 2022―Nov―13 COVID-19 Acute Respiratory Distress Syndrome promotes a specific alternative macrophage polarization Marc Garnier, Florian Blanchard, Arnaud Mailleux, Laurence Morand-Joubert, Bruno Crestani, Christophe Quesnel
10 [GO] 2022―Okt―21 Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies José Javier Morales-Núñez, José Francisco Muñoz-Valle, Andrea Carolina Machado-Sulbarán, Saúl Alberto Díaz-Pérez, Paola Carolina Torres-Hernández, Beatriz Verónica Panduro-Espinoza, et al. (+3)
11 [GO] 2022―Sep―27 SARS-CoV-2-specicific humoral immunity in convalescent patients with mild COVID-19 is supported by CD4+ T-cell help and negatively correlated with Alphacoronavirus-specific antibody titer Marcus Odendahl, Iris Endler, Beate Haubold, Roman N. Rodionov, Stefan R. Bornstein, Torsten Tonn
12 [GO] 2022―Sep―27 Immune, inflammatory and prothrombotic parameters in COVID-19 patients treated with an anti EGFR antibody. Danay Saavedra, Ana L. Añé-Kourí, Egda M. Llanez Gregorich, Jilma Mena, Patricia Lorenzo-Luaces, Henrry Diaz Londres, et al. (+8)
13 [GO] 2022―Sep―13 Full seroconversion in initial non-responders with higher antibody levels after heterologous COVID-19 vaccination schedule. Wagner Angelika, Anna Ohradanova-Repic, Laura Gebetsberger, Gabor Tajti, Kundi Michael, Stockinger Hannes, et al. (+2)
14 [GO] 2022―Aug―31 Novel skewed usage of B-cell receptors in COVID-19 patients with various clinical presentations Junpeng Ma, Han Bai, Tian Gong, Weikang Mao, Yijun Nie, Xuan Zhang, et al. (+8)
15 [GO] 2022―Jul―14 Diminished T-cell Immune Responses to SARS-CoV-2 Omicron Variant after BNT162b2 Vaccination Stanley C. Jordan, Bong-Ha Shin, Edgar Rodriguez, Vo Ashley, Ruan Zhang
16 [GO] 2022―Jul―08 Soluble CD137 as a potential biomarker for severe COVID-19 Mariana de Oliveira Marques, André Abdo, Priscilla Brito Silva, Amilton Silva Junior, Lucas Bassolli de Oliveira Alves, José Victor Gomes Costa, et al. (+3)
17 [GO] 2022―Mai―31 Could anti-ACE2 antibodies alter the results of SARS-CoV-2 Ab neutralization assays? Raquel Tobes
18 [GO] 2022―Feb―04 A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant. S.O Minka, F.H Minka
19 [GO] 2022―Jan―31 Immune system aging and the aging-related diseases in the COVID-19 era Jacek M. Witkowski
20 [GO] 2022―Jan―07 A novel antibody against the furin cleavage site of SARS-CoV-2 spike protein: effects on proteolytic cleavage and ACE2 binding Michael G. Spelios, Jeanne M. Capanelli, Adam W. Li
21 [GO] 2021―Sep―23 Targeting the PI3K/Akt/mTOR pathway: A therapeutic strategy in COVID-19 patients Rasha Abu-Eid, Frank James Ward
22 [GO] 2021―Jul―03 SARS-CoV-2 Spike protein enhances ACE2 expression via facilitating Interferon effects in bronchial epithelium Ye Zhou, Mu Wang, Yunhui Li, Peihui Wang, Ping Zhao, Zixuan Yang, et al. (+8)
23 [GO] 2021―Apr―24 Will a little change do you good? A putative role of polymorphisms in COVID-19 Adriana Alves Oliveira Paim, Ágata Lopes-Ribeiro, Daniele S.O. Daian e Silva, Luis Adan F. Andrade, Thais F. S Moraes, Edel F. Barbosa-Stancioli, et al. (+2)
24 [GO] 2021―Apr―24 HLA-C*17 in COVID-19 patients: hints for associations with severe clinical outcome and cardiovascular risk Irene Bonaccorsi, Paolo Carrega, Emmanuele Venanzi Rullo, Rosaria Ducatelli, Michela Falco, Josè Freni, et al. (+8)
25 [GO] 2021―Feb―10 Influence of aging on T cell response and renin-angiotensin system imbalance during SARS-CoV-2 infection Jorge Quarleri, Cintia Cevallos, M. Victoria Delpino
26 [GO] 2021―Jan―11 Did we forget the diffuse chemosensory system when studying COVID-19? Sheila Veronese, Flavia Merigo, Andrea Sbarbati
27 [GO] 2021―Jan―08 Immune reactivity during COVID-19: Implications for treatment Claudio Napoli, Giuditta Benincasa, Clelia Criscuolo, Mario Faenza, Cinzia Liberato, Mariangela Rusciano
28 [GO] 2021―Jan―02 Are the emerging SARS-COV-2 mutations friend or foe? Adnan Ero
29 [GO] 2020―Nov―05 Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab Lorenzo Salvati, Mariaelena Occhipinti, Leonardo Gori, Luca Ciani, Alessio Mazzoni, Laura Maggi, et al. (+7)
30 [GO] 2020―Sep―29 “Cytokine storm”, not only in COVID-19 patients. Mini-review Norbert Lukan
31 [GO] 2020―Jul―10 Intermittent fasting, a possible priming tool for host defense against SARS-CoV-2 infection: crosstalk among calorie restriction, autophagy and immune response Md. Abdul Hannan, Md. Ataur Rahman, Md Saidur Rahman, Abdullah Al Mamun Sohag, Raju Dash, Khandkar Shaharina Hossain, et al. (+2)
32 [GO] 2020―Jun―20 Lymphopenia during the COVID-19 infection: What it shows and what can be learned Soheil Tavakolpour, Taha Rakhshandehroo, Erin X. Wei, Mohammad Rashidian
33 [GO] 2020―Jun―11 Sequence homology between human PARP14 and the SARS-CoV-2 ADP ribose 1’-phosphatase E. Thomas, Ramy Saad
34 [GO] 2020―Jun―06 How nicotine can inhibit cytokine storm in the lungs and prevent or lessen the severity of COVID-19 infection? Malgorzata Kloc, Rafik M. Ghobrial, Jacek Z Kubiak
35 [GO] 2020―Mai―28 Are there any association between COVID-19 severity and immunosuppressive therapy? Ahmad Hormati, Mohammad Reza Ghadir, Farhad Zamani, Javad Khodadadi, Fatemeh Khodadust, Mahboubeh Afifian, et al. (+2)
 [1] 

35 Ergebisse       Seite 1



[de][en]

Letzte Änderung 2023―Okt―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.005 sec